Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11786524 Pharmaceutical compounds

Patent 11786524 was granted and assigned to Sentinel Oncology Limited on October, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Sentinel Oncology Limited

Current Assignee

Sentinel Oncology Limited

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

David Winter Walker

Richard Justin Boyce

Robert George Boyle

Scott Peterson

Francine Farouz

Cong Hung Vo

Date of Patent

October 17, 2023

Patent Application Number

17191151

Date Filed

March 3, 2021

Patent Citations

US Patent 8716287 Pharmaceutical compounds

US Patent 7642272 Cannabinoid receptor ligands

US Patent 7795288 Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors

US Patent 8314108 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts

US Patent 8822469 Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase

US Patent 9067920 Compounds useful for inhibiting Chk1

US Patent 9096602 Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors

US Patent 9255072 Pyrazole compounds and thiazole compounds as protein kinases inhibitors

...

Patent Primary Examiner

CPC Code

...

Patent abstract

This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11786524 Pharmaceutical compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.